Literature DB >> 20804810

Differential roles of phospholipases A2 in neuronal death and neurogenesis: implications for Alzheimer disease.

Evelin L Schaeffer1, Emanuelle R da Silva, Barbara de A Novaes, Heni D Skaf, Wagner F Gattaz.   

Abstract

The involvement of phospholipase A(2) (PLA(2)) in Alzheimer disease (AD) was first investigated nearly 15 years ago. Over the years, several PLA(2) isoforms have been detected in brain tissue: calcium-dependent secreted PLA(2) or sPLA(2) (IIA, IIC, IIE, V, X, and XII), calcium-dependent cytosolic PLA(2) or cPLA(2) (IVA, IVB, and IVC), and calcium-independent PLA(2) or iPLA(2) (VIA and VIB). Additionally, numerous in vivo and in vitro studies have suggested the role of different brain PLA(2) in both physiological and pathological events. This review aimed to summarize the findings in the literature relating the different brain PLA(2) isoforms with alterations found in AD, such as neuronal cell death and impaired neurogenesis process. The review showed that sPLA(2)-IIA, sPLA(2)-V and cPLA(2)-IVA are involved in neuronal death, whereas sPLA(2)-III and sPLA(2)-X are related to the process of neurogenesis, and that the cPLA(2) and iPLA(2) groups can be involved in both neuronal death and neurogenesis. In AD, there are reports of reduced activity of the cPLA(2) and iPLA(2) groups and increased expression of sPLA(2)-IIA and cPLA(2)-IVA. The findings suggest that the inhibition of cPLA(2) and iPLA(2) isoforms (yet to be determined) might contribute to impaired neurogenesis, whereas stimulation of sPLA(2)-IIA and cPLA(2)-IVA might contribute to neurodegeneration in AD.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20804810     DOI: 10.1016/j.pnpbp.2010.08.019

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  12 in total

Review 1.  Integrating cytosolic phospholipase A₂ with oxidative/nitrosative signaling pathways in neurons: a novel therapeutic strategy for AD.

Authors:  Grace Y Sun; Yan He; Dennis Y Chuang; James C Lee; Zezong Gu; Agnes Simonyi; Albert Y Sun
Journal:  Mol Neurobiol       Date:  2012-04-03       Impact factor: 5.590

Review 2.  Neuronal Cell Death.

Authors:  Michael Fricker; Aviva M Tolkovsky; Vilmante Borutaite; Michael Coleman; Guy C Brown
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

3.  Increased iPLA2 activity and levels of phosphorylated GSK3B in platelets are associated with donepezil treatment in Alzheimer's disease patients.

Authors:  L L Talib; S R Hototian; H P G Joaquim; O V Forlenza; W F Gattaz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-04-29       Impact factor: 5.270

4.  Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease.

Authors:  Luke Whiley; Arundhuti Sen; James Heaton; Petroula Proitsi; Diego García-Gómez; Rufina Leung; Norman Smith; Madhav Thambisetty; Iwona Kloszewska; Patrizia Mecocci; Hilkka Soininen; Magda Tsolaki; Bruno Vellas; Simon Lovestone; Cristina Legido-Quigley
Journal:  Neurobiol Aging       Date:  2013-09-13       Impact factor: 4.673

5.  Conjugated linoleic acid-enriched butter improved memory and up-regulated phospholipase A2 encoding-genes in rat brain tissue.

Authors:  Marco A S Gama; Nádia R B Raposo; Fábio B Mury; Fernando C F Lopes; Emmanuel Dias-Neto; Leda L Talib; Wagner F Gattaz
Journal:  J Neural Transm (Vienna)       Date:  2015-04-26       Impact factor: 3.575

6.  Lysophosphatidylcholine Drives Neuroblast Cell Fate.

Authors:  Luciana Paoletti; Pablo Domizi; Hebe Marcucci; Aneley Montaner; Dario Krapf; Gabriela Salvador; Claudia Banchio
Journal:  Mol Neurobiol       Date:  2015-11-14       Impact factor: 5.590

7.  Low platelet iPLA₂ activity predicts conversion from mild cognitive impairment to Alzheimer's disease: a 4-year follow-up study.

Authors:  Wagner F Gattaz; Leda L Talib; Evelin L Schaeffer; Breno S Diniz; Orestes V Forlenza
Journal:  J Neural Transm (Vienna)       Date:  2013-09-15       Impact factor: 3.575

8.  β-Sheet Breaker Peptide-HPYD for the Treatment of Alzheimer's Disease: Primary Studies on Behavioral Test and Transcriptional Profiling.

Authors:  Weiying Liu; Fengxian Sun; Moxin Wan; Fang Jiang; Xiangyu Bo; Laixiang Lin; Hua Tang; Shumei Xu
Journal:  Front Pharmacol       Date:  2018-01-08       Impact factor: 5.810

9.  Enhanced Phospholipase A2 Group 3 Expression by Oxidative Stress Decreases the Insulin-Degrading Enzyme.

Authors:  Daishi Yui; Yoichiro Nishida; Tomoko Nishina; Kaoru Mogushi; Mio Tajiri; Satoru Ishibashi; Itsuki Ajioka; Kinya Ishikawa; Hidehiro Mizusawa; Shigeo Murayama; Takanori Yokota
Journal:  PLoS One       Date:  2015-12-04       Impact factor: 3.240

10.  White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer's Disease.

Authors:  Lauren P Klosinski; Jia Yao; Fei Yin; Alfred N Fonteh; Michael G Harrington; Trace A Christensen; Eugenia Trushina; Roberta Diaz Brinton
Journal:  EBioMedicine       Date:  2015-11-03       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.